Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
RESEARCH TOOLSreports
Holding TSE:GUD?
Track your performance easily
GUD Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$5.09 - C$6.23
Previous CloseC$5.19
Volume82.14K
Average Volume (3M)114.66K
Market Cap
C$517.52M
Enterprise ValueC$428.01M
Total Cash (Recent Filing)C$147.72M
Total Debt (Recent Filing)C$58.22M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Mar 20, 2025EPS Estimate
C$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding101,214,097
10 Day Avg. Volume73,239
30 Day Avg. Volume114,658
Standard Deviation0.06
R-Squared0.14
Alpha-0.00870
Financial Highlights & Ratios
Price to Book (P/B)0.68
Price to Sales (P/S)1.50
Price to Cash Flow (P/CF)26.00
P/FCF Ratio40.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$7.30Price Target Upside40.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Knight Therapeutics News
PremiumCompany Announcements
Knight Therapeutics Reports Q3 2024 Financial Results
Options Prices
Currently, No data available
---
Ownership Overview
34.98% Insiders
2.05% Mutual Funds
0.09% Other Institutional Investors
62.36% Public Companies and
Individual Investors
GUD FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was C$5.08 and its highest was C$6.23 in the past 12 months.
What is Knight Therapeutics’s market cap?
Currently, no data Available
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 88 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Nov 07, 2024. The company reported C$0 earnings per share for the quarter, missing the consensus estimate of C$0.018 by -C$0.018.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is C$0.02.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 100,293,860 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of C$0 in its last earnings report, missing expectations of C$0.018. Following the earnings report the stock price went down -10.279%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in TSE:GUD
---
Knight Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$7.30 (40.59% Upside)
C$7.30 (40.59% Upside)
Insider Transactions
Sold Shares
Worth $853.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.45%
12-Months-Change
Fundamentals
Return on Equity
-3.84%
Trailing 12-Months
Asset Growth
-4.76%
Trailing 12-Months
Company Description
Knight Therapeutics
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.
---
GUD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted record revenue growth and successful product launches, along with a strong pipeline. However, challenges such as declining gross margins, decreased adjusted EBITDA, and currency depreciation were noted.Read More>---
GUD Stock 12 Month Forecast
Average Price Target
C$7.30
▲(40.59% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
BioCryst
―
Clearside Biomedical
―
Knight Therapeutics
―
Durect
―
Best Analysts Covering GUD
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
-5.73%
reiterated a buy rating 2 months ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of -5.73% per trade.
---